摘要
DDR (DNA damage response) defects in cells drive tumor formation by promoting DNA mutations, which also provides cancer-specific vulnerabilities that can be targeted by synthetic lethality-based therapies. Until now, PARP inhibitors like olaparib are the first successful case of utilizing synthetic lethality-based therapy to treat cancers with DNA-repairing deficiency (e.g. BRCA1 or BRCA2 mutation), which has fueled the search for more targetable components in the DDR signaling pathway by exploiting synthetic lethality, including but not limited to DNA-PK, ATR, ATM, CHK1, and WEE1. After years of efforts, numerous DDR kinase inhibitors have been discovered. Some of them are being investigated in clinical trials and have shown promising results for cancer therapy. In this review, we summarize the latest advancement in the development of DDR kinase inhibitors including those in preclinical stages and clinical trials, the crystal structures of DDR enzymes, and binding modes of inhibitors with target proteins. The biological functions involving different genes and proteins (ATR, DNA-PK, ATM, PARP, CHK1, and WEE1) are also elucidated.
学科与关键词
- Role of deubiquitinases in DNA damage response.Le John; Perez Eric; Nemzow Leah; Gong Feng*DNA Repair (Amst), 2019, 76: 89-98.
- Structural insights into the critical DNA damage sensors DNA-PKcs, ATM and ATRDomagoj Baretic; Taiana Maia de Oliveira; Martina Niess; Paul Wan; Hannah Pollard; Christopher M Johnson; Caroline Truman; Eileen McCall; David Fisher; Roger Williams; Christopher PhillipsPROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY, 2019.
- The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapyShi, Congqi; Qin, Kaiyu; Lin, Anqi; Jiang, Aimin; Cheng, Quan; Liu, Zaoqu; Zhang, Jian*; Luo, Peng*JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41(1): 268.被引 16
